@nejm - Twitter Profile Analysis

Analysis of 200 tweets by NEJM, from 29 Jul 2021 to 18 Sep 2021.

@nejm twitter profile photo

NEJM

verified twitter profile @NEJM

The New England Journal of Medicine (http://t.co/YKINVyRNEl) is the world’s leading medical journal and website.

Nord VPN - Browse in full privacy

24,445 tweets
853,615 followers
1,079 favourites
4 tweets per day
2009 since
395 following
9,957 listed
Boston, MA location

Top Tweets by @nejm

NEJM
@NEJM
Quick Take: Salt Substitute and Cardiovascular Events https://t.co/0MNvqtd04A
18 Sep, 2021 - 02:00 PM UTC
NEJM
@NEJM
KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
18 Sep, 2021 - 01:15 PM UTC
NEJM
@NEJM
DESTINY-Lung01: Trastuzumab deruxtecan showed durable anticancer activity in 91 patients with HER2-mutant NSCLC. Safety profile included interstitial lung disease that was fatal in two. #ESMO21 https://t.co/mM03Lr1MyH
18 Sep, 2021 - 12:35 PM UTC
NEJM
@NEJM
Erin Fuse Brown discusses lessons from U.S. states that have enacted public option health plans. https://t.co/REKZ6qxnYm
17 Sep, 2021 - 04:00 PM UTC
NEJM
@NEJM
Treatment for acute uncomplicated appendicitis may involve appendectomy or nonoperative care. Shared decision making is recommended. https://t.co/EzMUaJO2Lk
17 Sep, 2021 - 02:30 PM UTC
NEJM
@NEJM
A 26-year-old woman with two prior cesarean deliveries presented in preterm labor. Placental vessels were visualized during surgery. https://t.co/jw5E5g2QzM
17 Sep, 2021 - 01:00 PM UTC
NEJM
@NEJM
As of July 29, 2021, a total of 2022 cases of congenital syphilis were reported to the CDC, surpassing the number of cases reported in 2019 and the highest case count since 1994. https://t.co/TtbsikobRx
16 Sep, 2021 - 10:15 PM UTC
NEJM
@NEJM
Public Option 2.0 may be the most realistic way to guarantee universal coverage with a broad choice of providers and with medical prices held down by the government. https://t.co/GQ7PHDuMQ1
16 Sep, 2021 - 04:30 PM UTC
NEJM
@NEJM
Incidence of blood-culture confirmed typhoid fever lower among children who received Vi-TCV vaccine than those who received control. https://t.co/vS0kJZgwNj
16 Sep, 2021 - 02:15 PM UTC
NEJM
@NEJM
In this audio interview conducted on September 14, the editors discuss new studies that measure the effectiveness of booster doses in raising antibody levels and protecting against Covid-19. https://t.co/8PGiPaxddn
16 Sep, 2021 - 01:00 PM UTC
NEJM
@NEJM
In study of participants in Israel who were 60+, the rates of confirmed #COVID19 & severe illness were substantially lower after a booster (third) dose of the BNT162b2 vaccine than after two doses. #SARSCoV2 #Covid19Vaccines #IDTwitter https://t.co/aOPyI7Y23s
16 Sep, 2021 - 12:00 PM UTC
NEJM
@NEJM
Safety & immunogenicity of a booster dose of BNT162b2 given 7 to 9 mos after two-dose series suggest that a third dose could prolong protection and further increase the breadth of protection. #Covid19Vaccines #COVID19 #SARSCoV2 #IDTwitter https://t.co/Z2USaFtfA9
15 Sep, 2021 - 09:40 PM UTC
NEJM
@NEJM
Experience with 11 patients suggests that elements of VITT (severe headache, elevated d-dimer levels, and positivity for anti-PF4 antibodies) after ChAdOx1 nCoV-19 vaccination may precede VITT. #Covid19Vaccines #COVID19 #SARSCoV2 #IDTwitter https://t.co/mzBgjJIE6l
15 Sep, 2021 - 09:30 PM UTC
NEJM
@NEJM
At 6 months, the vaccine efficacy of BNT162b2 was 91% against #COVID19 and 97% against severe disease. In S Africa, where the beta variant was widespread, vaccine efficacy was 100%. #Covid19Vaccines #SARSCoV2 #IDTwitter https://t.co/LpQHw0SlXD
15 Sep, 2021 - 09:20 PM UTC
NEJM
@NEJM
Quick Take: Functional Benefits of Infant Iron Interventions https://t.co/Xl0Rde4mda
15 Sep, 2021 - 04:00 PM UTC

Top Retweets by @nejm

NEJM Evidence
@NEJMEvidence
Make clinical decisions based on evidence, not on convention. NEJM Evidence, launching early 2022. https://t.co/oT13ZTHsub
17 Sep, 2021 - 12:00 PM UTC
NEJM Evidence
@NEJMEvidence
Launching early 2022. NEJM Evidence, a new monthly digital journal from @NEJMGroup, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. Learn more: https://t.co/oT13ZTHsub
16 Sep, 2021 - 01:00 PM UTC
NEJM Catalyst
@nejmcatalyst
Our September issue explores difficult care for complex patients, Covid-19 #AdvanceCarePlanning, monoclonal antibody therapy distribution, transfers between collaborating hospitals, cataract surgery comparisons in three countries, and #DementiaCare: https://t.co/g6qzCkX3Qc
18 Aug, 2021 - 01:25 PM UTC
NEJM Journal Watch
@JWatch
Post-vaccination SARS-CoV-2 infections were generally mild or asymptomatic in healthcare workers who had received the Pfizer BNT162b2 #vaccine: https://t.co/eCtKaAQIMS #COVID19
13 Aug, 2021 - 07:14 PM UTC
NEJM Journal Watch
@JWatch
#COVID19 is an independent risk factor for acute myocardial infarction and ischemic stroke, suggest population-based studies in Sweden. https://t.co/gYoCLpvmjJ @hmkyale
10 Aug, 2021 - 07:35 PM UTC
NEJM Journal Watch
@JWatch
In deceased #COVID19 patients, gene expression in the choroid plexus was altered. https://t.co/B4xFh2uv63 #neurology
05 Aug, 2021 - 01:37 PM UTC
NEJM Journal Watch
@JWatch
The new KDIGO guideline addresses #bloodpressure measurement, targets, and medications for patients with chronic kidney disease. https://t.co/JelXjSkrFq #hypertension #CKD
01 Aug, 2021 - 06:00 PM UTC

@nejm's

Tweets

193 tweets
7 retweets
0 replies
@nejm's

Twitter Client

154 Emplifi
14 Twitter for Advertisers
10 Twitter Media Studio
9 Twitter for Advertisers.
@nejm's

Tweet Times

@nejm's

Tweet Days


@nejm's

Retweets

4 - JWatch
2 - NEJMEvidence
1 - nejmcatalyst
@nejm's

Replies

No replies found.
@nejm's

Hashtags

39 - #COVID19
29 - #IDTwitter
16 - #SARSCoV2
11 - #ESCCongress
11 - #Covid19Vaccines
2 - #Covid19vaccine
2 - #HealthyClimate
2 - #ESMO21
@nejm's

Mentions

2 - @NEJM
1 - @PaulSaxMD

Microsoft Office